研究者業績

小野 啓

オノ ヒラク  (Hiraku Ono)

基本情報

所属
千葉大学 予防医学センター 教授
学位
医学博士(2001年3月 東京大学)

J-GLOBAL ID
200901067300291495
researchmap会員ID
5000005052

学歴

 2

委員歴

 1

論文

 117
  • 越坂 理也, 横尾 英孝, 長島 健悟, 佐藤 泰憲, 前田 祐香里, 武田 健治, 石川 耕, 小野 啓, 齋木 厚人, 龍野 一郎, 津下 一代, 高原 充佳, 下村 伊一郎, 笹子 敬洋, 門脇 孝, 横手 幸太郎
    糖尿病 67(Suppl.1) S-215 2024年4月  
  • Takeshi Yamamotoya, Yukino Ohata, Yasuyuki Akasaka, Shun Hasei, Masa-Ki Inoue, Yusuke Nakatsu, Machi Kanna, Hiroki Yamazaki, Akifumi Kushiyama, Midori Fujishiro, Hiraku Ono, Hideyuki Sakoda, Tetsuya Yamada, Hisamitsu Ishihara, Tomoichiro Asano
    PNAS nexus 3(4) pgae150 2024年4月  
    Mutations in the Trk-fused gene (TFG) cause hereditary motor and sensory neuropathy with proximal dominant involvement, which reportedly has high co-incidences with diabetes and dyslipidemia, suggesting critical roles of the TFG in metabolism as well. We found that TFG expression levels in white adipose tissues (WATs) were elevated in both genetically and diet-induced obese mice and that TFG deletion in preadipocytes from the stromal vascular fraction (SVF) markedly inhibited adipogenesis. To investigate its role in vivo, we generated tamoxifen-inducible adipocyte-specific TFG knockout (AiTFG KO) mice. While a marked down-regulation of the peroxisome proliferator-activated receptor gamma target, de novo lipogenesis (DNL), and mitochondria-related gene expressions were observed in subcutaneous WAT (scWAT) from AiTFG KO mice, these effects were blunted in SVF-derived adipocytes when the TFG was deleted after differentiation into adipocytes, implying cell nonautonomous effects. Intriguingly, expressions of thyroid hormone receptors, as well as carbohydrate responsive element-binding protein β, which mediates the metabolic actions of thyroid hormone, were drastically down-regulated in scWAT from AiTFG KO mice. Reduced DNL and thermogenic gene expressions in AiTFG KO mice might be attributable to impaired thyroid hormone action in vivo. Finally, when adipocyte TFG was deleted in either the early or the late phase of high-fat diet feeding, the former brought about an impaired expansion of epididymal WAT, whereas the latter caused prominent adipocyte cell death. TFG deletion in adipocytes markedly exacerbated hepatic steatosis in both experimental settings. Collectively, these observations indicate that the TFG plays essential roles in maintaining normal adipocyte functions, including an enlargement of adipose tissue, thyroid hormone function, and thermogenic gene expressions, and in preserving hypertrophic adipocytes.
  • Takuya Minamizuka, Junji Kobayashi, Hayato Tada, Masaya Koshizaka, Yoshiro Maezawa, Hiraku Ono, Koutaro Yokote
    Internal medicine (Tokyo, Japan) 63(15) 2137-2142 2024年  
    The patient was a 54-year-old woman with familial hypercholesterolemia and remarkable Achilles tendon thickening. At 20 years old, the patient had a total cholesterol level of approximately 300 mg/dL. She started receiving rosuvastatin (5 mg/day) for low-density lipoprotein cholesterol (LDL-C) 235 mg/dL at 42 years old, which was increased to 10 mg/day at 54 years old, decreasing her serum LDL-C level to approximately 90 mg/dL. The serum Lp (a) level was 9 mg/dL. A computed tomography coronary angiogram showed no significant stenosis. Next-generation sequencing revealed a frameshift variant in LDL receptor (LDLR) (heterozygous) and a missense variant in proprotein convertase subtilisin/kaxin type 9 (PCSK9) (heterozygous). Continued statin therapy, in addition to low Lp (a) and female sex, can help prevent cardiovascular disease.
  • Shinsuke Sakai, Youichi Tanaka, Yusuke Tsukamoto, Shihoko Kimura-Ohba, Atsushi Hesaka, Kenji Hamase, Chin-Ling Hsieh, Eiryo Kawakami, Hiraku Ono, Kotaro Yokote, Mitsuaki Yoshino, Daisuke Okuzaki, Hiroyo Matsumura, Atsuko Fukushima, Masashi Mita, Maiko Nakane, Masao Doi, Yoshitaka Isaka, Tomonori Kimura
    Kidney360 2023年12月15日  
    BACKGROUND: The aberrant glucose circadian rhythm is associated with the pathogenesis of diabetes. Similar to glucose metabolism in kidney and liver, d-alanine, a rare enantiomer of alanine, shows circadian alteration, although the effect of d-alanine on glucose metabolism has not been explored. Here we show that d-alanine acts on the circadian clock and affects glucose metabolism in the kidney. METHODS: The blood and urinary levels of d-alanine in mice were measured using two-dimensional high performance liquid chromatography system. Metabolic effects of d-alanine were analysed in mice and in primary culture of kidney proximal tubular cells from mice. Behavioural and gene expression analyses of circadian rhythm were performed using mice bred under constant darkness. RESULTS: d-Alanine levels in blood exhibited a clear intrinsic circadian rhythm. Since this rhythm was regulated by the kidney through urinary excretion, we examined the effect of d-alanine on kidney. In kidney, d-alanine induced expressions of genes involved in gluconeogenesis and circadian rhythm. Treatment of d-alanine mediated glucose production in mice. Ex vivo glucose production assay demonstrated that treatment of d-alanine induced glucose production in primary culture of kidney proximal tubular cells, where d-amino acids are known to be reabsorbed, but not in that of liver cells. Gluconeogenetic effect of d-alanine has an intraday variation, and this effect was in part mediated through circadian transcriptional network. Under constant darkness, treatment of d-alanine normalized the circadian cycle of behaviour and kidney gene expressions. CONCLUSIONS: d-Alanine induces gluconeogenesis in the kidney and adjusts the period of the circadian clock. Normalization of circadian cycle by d-alanine may provide the therapeutic options for life style-related diseases and shift workers.
  • Yasuyuki Akasaka, Shun Hasei, Yukino Ohata, Machi Kanna, Yusuke Nakatsu, Hideyuki Sakoda, Midori Fujishiro, Akifumi Kushiyama, Hiraku Ono, Akio Matsubara, Nobuyuki Hinata, Tomoichiro Asano, Takeshi Yamamotoya
    International journal of molecular sciences 24(21) 2023年11月6日  
    Citrus hassaku extract reportedly activates AMPK. Because this extract contains an abundance of auraptene, we investigated whether pure auraptene activates AMPK and inhibits proliferation using prostate cancer cell lines. Indeed, auraptene inhibited the proliferation and migration of LNCaP cells and induced phosphorylation of AMPK or its downstream ACC in LNCaP, PC3, and HEK-293 cells, but not in DU145 cells not expressing LKB1. In addition, the mTOR-S6K pathway, located downstream from activated AMPK, was also markedly suppressed by auraptene treatment. Importantly, it was shown that auraptene reduced androgen receptor (AR) and prostate-specific antigen (PSA) expressions at both the protein and the mRNA level. This auraptene-induced downregulation of PSA was partially but significantly reversed by treatment with AMPK siRNA or the AMPK inhibitor compound C, suggesting AMPK activation to, at least partially, be causative. Finally, in DU145 cells lacking the LKB1 gene, exogenously induced LKB1 expression restored AMPK phosphorylation by auraptene, indicating the essential role of LKB1. In summary, auraptene is a potent AMPK activator that acts by elevating the AMP/ATP ratio, thereby potentially suppressing prostate cancer progression, via at least three molecular mechanisms, including suppression of the mTOR-S6K pathway, reduced lipid synthesis, and AR downregulation caused by AMPK activation.

MISC

 89
  • 大西 由希子, 荻原 健英, 穴井 元暢, 迫田 秀之, 小野 啓, 浅野 知一郎, 菊池 方利
    糖尿病 47(Suppl.1) S203-S203 2004年4月  
  • H Ono, H Shimano, N Yahagi, T Ogihara, H Katagiri, H Sakoda, Y Onishi, N Shojima, M Kikuchi, NH Yamada, T Asano
    DIABETES 52 A301-A301 2003年6月  
  • 大西 由希子, 迫田 秀之, 小野 啓, 春日 広一, 穴井 元暢, 菊池 方利
    糖尿病 46(4) 347-347 2003年4月  
  • 庄嶋 伸浩, 迫田 秀之, 荻原 健英, 穴井 元暢, 大西 由希子, 小野 啓, 藤城 緑, 本田 美穂, 犬飼 浩一, 片桐 秀樹, 菊池 方利, 岡 芳知, 浅野 知一郎
    日本内分泌学会雑誌 79(1) 190-190 2003年4月  
  • 浅野 知一郎, 小野 啓, 荻原 健英, 藤城 緑, 庄嶋 伸吾, 迫田 秀之, 大西 由希子, 菊池 方利
    糖尿病 46(Suppl.1) S312-S312 2003年4月  
  • 藤城 緑, 片桐 秀樹, 後藤 由季子, 佃 克則, 穴井 元暢, 迫田 秀之, 大西 由希子, 小野 啓, 阿部 美穂, 庄嶋 伸浩, 菊池 方利, 浅野 知一郎
    Diabetes Frontier 14(1) 114-114 2003年2月  
  • Fujishiro Midori, Gotoh Yukiko, Katagiri Hideki, Sakoda Hideyuki, Ogihara Takehide, Anai Motonobu, Onishi Yukiko, Ono Hiraku, Abe Miho, Shojima Nobuhiro, Fukushima Yasushi, Kikuchi Masatoshi, Oka Yoshitomo, Asano Tomoichiro
    Mol Endocrinol 17(3) 487-497 2003年  
    <title>Abstract</title>TNFα, which activates three different MAPKs [ERK, p38, and jun amino terminal kinase (JNK)], also induces insulin resistance. To better understand the respective roles of these three MAPK pathways in insulin signaling and their contribution to insulin resistance, constitutively active MAPK/ERK kinase (MEK)1, MAPK kinase (MKK6), and MKK7 mutants were overexpressed in 3T3-L1 adipocytes using an adenovirus-mediated transfection procedure. The MEK1 mutant, which activates ERK, markedly down-regulated expression of the insulin receptor (IR) and its major substrates, IRS-1 and IRS-2, mRNA and protein, and in turn reduced tyrosine phosphorylation of IR as well as IRS-1 and IRS-2 and their associated phosphatidyl inositol 3-kinase (PI3K) activity. The MKK6 mutant, which activates p38, moderately inhibited IRS-1 and IRS-2 expressions and IRS-1-associated PI3K activity without exerting a significant effect on the IR. Finally, the MKK7 mutant, which activates JNK, reduced tyrosine phosphorylation of IRS-1 and IRS-2 and IRS-associated PI3K activity without affecting expression of the IR, IRS-1, or IRS-2. In the context of our earlier report showing down-regulation of glucose transporter 4 by MEK1-ERK and MKK6/3-p38, the present findings suggest that chronic activation of ERK, p38, or JNK can induce insulin resistance by affecting glucose transporter expression and insulin signaling, though via distinctly different mechanisms. The contribution of ERK is, however, the strongest.
  • Onishi Yukiko, Honda Miho, Ogihara Takehide, Sakoda Hideyuki, Anai Motonobu, Fujishiro Midori, Ono Hiraku, Shojima Nobuhiro, Fukushima Yasushi, Inukai Kouichi, Katagiri Hideki, Kikuchi Masatoshi, Oka Yoshitomo, Asano Tomoichiro
    Biochem Biophys Res Commun 303(3) 788-794 2003年  
  • Sakoda Hideyuki, Gotoh Yukiko, Katagiri Hideki, Kurokawa Mineo, Ono Hiraku, Onishi Yukiko, Anai Motonobu, Ogihara Takehide, Fujishiro Midori, Fukushima Yasushi, Abe Miho, Shojima Nobuhiro, Kikuchi Masatoshi, Oka Yoshitomo, Hirai Hisamaru, Asano Tomoichiro
    J Biol Chem 278(28) 25802-25807 2003年  
  • 迫田 秀之, 大西 由希子, 小野 啓, 春日 広一, 穴井 元暢, 菊池 方利, 庄嶋 伸浩
    糖尿病 45(6) 437-437 2002年6月  
  • 児島 そのえ, 柳澤 恵美子, 萩原 結花, 荻原 健英, 小野 啓, 大西 由希子, 迫田 秀之, 穴井 元暢, 菊池 方利
    糖尿病 45(Suppl.2) S94-S94 2002年4月  
  • 熊倉 淳, 鈴木 孝典, 金澤 真雄, 能登谷 洋子, 林 徹, 小野 啓, 大西 由希子, 迫田 秀之, 穴井 元暢, 菊池 方利
    糖尿病 45(Suppl.2) S292-S292 2002年4月  
  • 庄嶋 伸浩, 浅野 知一郎, 佃 克則, 片桐 秀樹, 犬飼 浩一, 穴井 元暢, 荻原 健英, 迫田 秀之, 大西 由希子, 小野 啓, 藤城 緑, 阿部 美穂, 菊池 方利, 木村 哲
    糖尿病 45(Suppl.2) S225-S225 2002年4月  
  • 荻原 健英, 浅野 知一郎, 迫田 秀之, 穴井 元暢, 大西 由希子, 小野 啓, 犬飼 浩一, 佃 克則, 菊池 方利, 木村 哲
    糖尿病 45(Suppl.2) S58-S58 2002年4月  
  • 迫田 秀之, 浅野 知一郎, 佃 克紀, 犬飼 浩一, 荻原 健英, 大西 由希子, 小野 啓, 藤城 緑, 庄嶋 伸浩, 菊池 方利
    糖尿病 45(Suppl.2) S59-S59 2002年4月  
  • 大西 由希子, 浅野 知一郎, 荻原 健英, 阿部 美穂, 迫田 秀之, 穴井 元暢, 小野 啓, 藤城 緑, 片桐 秀樹, 菊池 方利
    糖尿病 45(Suppl.2) S107-S107 2002年4月  
  • 阿部 美穂, 浅野 知一郎, 佃 克則, 片桐 秀樹, 犬飼 浩一, 穴井 元暢, 荻原 健英, 迫田 秀之, 大西 由希子, 小野 啓, 藤城 緑, 菊池 方利, 木村 哲
    糖尿病 45(Suppl.2) S225-S225 2002年4月  
  • Sakoda Hideyuki, Ogihara Takehide, Anai Motonobu, Fujishiro Midori, Ono Hiraku, Onishi Yukiko, Katagiri Hideki, Abe Miho, Fukushima Yasushi, Shojima Nobuhiro, Inukai Kouichi, Kikuchi Masatoshi, Oka Yoshitomo, Asano Tomoichiro
    Am J Physiol Endocrinol Metab 282(6) E1239-44 2002年  
  • Song Haiyan, Shojima Nobuhiro, Sakoda Hideyuki, Ogihara Takehide, Fujishiro Midori, Katagiri Hideki, Anai Motonobu, Onishi Yukiko, Ono Hiraku, Inukai Kouichi, Fukushima Yasushi, Kikuchi Masatoshi, Shimano Hitoshi, Yamada Nobuhiro, Oka Yoshitomo, Asano Tomoichiro
    Biochem Biophys Res Commun 299(2) 291-298 2002年  
  • 藤城 緑, 片桐 秀樹, 後藤 由季子, 犬飼 浩一, 小野 啓, 大西 由希子, 菊池 方利, 浅野 知一郎
    Diabetes Frontier 12(5) 663-664 2001年10月  
  • 穴井 元暢, 浅野 知一郎, 荻原 健英, 犬飼 浩一, 佃 克則, 小野 啓, 大西 由希子, 藤城 緑, 庄嶋 伸浩, 菊池 方利
    糖尿病 44(Suppl.1) S214-S214 2001年3月  
  • 藤城 緑, 浅野 知一郎, 片桐 秀樹, 犬飼 浩一, 荻原 健英, 迫田 秀之, 大西 由希子, 小野 啓, 菊池 方利, 木村 哲
    糖尿病 44(Suppl.1) S73-S73 2001年3月  
  • 大西 由希子, 浅野 知一郎, 荻原 健英, 迫田 秀之, 片桐 秀樹, 穴井 元暢, 小野 啓, 藤城 緑, 阿部 美穂, 菊池 方利
    糖尿病 44(Suppl.1) S75-S75 2001年3月  
  • 片桐 秀樹, 浅野 知一郎, 小野 啓, 藤城 緑, 木村 哲, 犬飼 浩一, 山田 哲也, 保坂 利男, 岡 芳知
    糖尿病 44(Suppl.1) S76-S76-S76 2001年  
  • 浅野知一郎, 船木真理, 片桐秀樹, 犬飼浩一, 小野啓, 大西由希子, 菊池方利
    Diabetes Frontier 11(5) 759-759 2000年10月  
  • 小野 啓, 浅野 知一郎, 藤城 緑, 迫田 秀之, 大西 由希子, 船木 真理, 穴井 元暢, 佃 克則, 菊池 方利, 木村 哲
    糖尿病 43(Suppl.1) 178-178 2000年4月  
  • 藤城 緑, 浅野 知一郎, 縄野 雅夫, 犬飼 浩一, 大西 由希子, 小野 啓, 迫田 秀之, 荻原 健英, 菊池 方利, 木村 哲
    糖尿病 43(Suppl.1) 99-99 2000年4月  
  • 佃 克則, 浅野 知一郎, 片桐 秀樹, 犬飼 浩一, 穴井 元暢, 大西 由希子, 小野 啓, 藤城 緑, 岡 芳知, 木村 哲
    糖尿病 43(Suppl.1) 113-113 2000年4月  
  • 船木 真理, 浅野 知一郎, 佃 克則, 片桐 秀樹, 犬飼 浩一, 大西 由希子, 迫田 秀之, 小野 啓, 阿部 美穂, 菊池 方利
    糖尿病 43(Suppl.1) 188-188 2000年4月  
  • Kouichi Inukai, Makoto Funaki, Masao Nawano, Hideki Katagiri, Takehide Ogihara, Motonobu Anai, Yukiko Onishi, Hideyuki Sakoda, Hiraku Ono, Yasushi Fukushima, Masatoshi Kikuchi, Yoshitomo Oka, Tomoichiro Asano
    Biochemical Journal 346(2) 483-489 2000年3月1日  
    There are five regulatory subunit isoforms of phosphoinositide 3-kinase (PI 3-kinase), which are classified into three groups: proteins of 85 kDa (p85α and p85β), 55 kDa (p55α and p55γ) and 50 kDa (p50α). Structural differences between the three groups reside in the N-terminus. To elucidate the unique functional role of the 55 kDa regulatory subunits, GST (glutathione S-transferase) fusion proteins containing a unique N-terminal portion consisting of a 34-amino-acid sequence of p55α or p55γ (GST-p55α/γN1-34) were used as affinity matrices to screen rat brain cell extracts for proteins to which this portion binds specifically. A protein that bound was identified as β-tubulin by protein sequencing. In addition, not only the β isoform of tubulin, but also the α and γ isoforms, were detected in the protein absorbed from cell lysates with GST-p55γN1-34 and GST-p55αN1-34 by immunoblotting. Indeed, the only regulatory subunit present in the purified microtubule assembly from rat brain was the 55 kDa isoform neither 85 kDa nor 50 kDa subunits were detected. These results indicate endogenous binding of 55 kDa regulatory subunits of PI 3-kinase to tubulin in the brain. Finally, we measured tubulin-associated PI 3-kinase activity in CHO/IR cells overexpressing each of the five regulatory subunit isoforms. Only in cells expressing p55α or p55γ was there a significant elevation of tubulin-associated PI 3-kinase activity in response to insulin. These results suggest that the p55α and p55γ regulatory subunits have important roles in regulating PI 3-kinase activity, particularly for microtubules at the cell periphery.
  • Hideyuki Sakoda, Takehide Ogihara, Motonobu Anai, Makoto Funaki, Kouichi Inukai, Hideki Katagiri, Yasushi Fukushima, Yukiko Onishi, Hiraku Ono, Midori Fujishiro, Masatoshi Kikuchi, Yoshitomo Oka, Tomoichiro Asano
    Diabetes 49(10) 1700-1708 2000年  
    Glucocorticoids reportedly induce insulin resistance. In this study, we investigated the mechanism of glucocorticoid-induced insulin resistance using 3T3-L1 adipocytes in which treatment with dexamethasone has been shown to impair the insulin-induced increase in glucose uptake. In 3T3-L1 adipocytes treated with dexamethasone, the GLUT1 protein expression level was decreased by 30%, which possibly caused decreased basal glucose uptake. On the other hand, dexamethasone treatment did not alter the amount of GLUT4 protein in total cell lysates but decreased the insulin-stimulated GLUT4 translocation to the plasma membrane, which possibly caused decreased insulin-stimulated glucose uptake. Dexamethasone did not alter tyrosine phosphorylation of insulin receptors, and it significantly decreased protein expression and tyrosine phosphorylation of insulin receptor substrate (IRS)-1. Interestingly, however, protein expression and tyrosine phosphorylation of IRS-2 were increased. To investigate whether the reduced IRS-1 content is involved in insulin resistance, IRS-1 was overexpressed in dexamethasone-treated 3T3-L1 adipocytes using an adenovirus transfection system. Despite protein expression and phosphorylation levels of IRS-1 being normalized, insulin-induced 2-deoxy-D-[3H]glucose uptake impaired by dexamethasone showed no significant improvement. Subsequently, we examined the effect of dexamethasone on the glucose uptake increase induced by overexpression of GLUT2-tagged p110α, constitutively active Akt (myristoylated Akt), oxidative stress (30 mU glucose oxidase for 2 h), 2 mmol/l 5-aminoimidazole-4-carboxamide ribonucleoside for 30 min, and osmotic shock (600 mmol/l sorbitol for 30 min). Dexamethasone treatment clearly inhibited the increases in glucose uptake produced by these agents. Thus, in conclusion, the GLUT1 decrease may be involved in the dexamethasone-induced decrease in basal glucose transport activity, and the mechanism of dexamethasone-induced insulin resistance in glucose transport activity (rather than the inhibition of phosphatidylinositol 3-kinase activation resulting from a decreased IRS-1 content) is likely to underlie impaired glucose transporter regulation.
  • 小野 啓, 浅野 知一郎, 佃 克則, 犬飼 浩一, 大西 由希子, 藤城 緑, 岡田 光正, 能登 洋, 磯尾 直之, 田村 嘉章
    糖尿病 42(10) 874-874 1999年10月  
  • 佃 克則, 浅野 知一郎, 穴井 元暢, 大西 由希子, 小野 啓, 木村 哲, 細川 和広, 渥美 義仁, 松岡 健平, 飯島 敏彦
    糖尿病 42(Suppl.1) S254-S254 1999年4月  
  • 船木 真理, 浅野 知一郎, 片桐 秀樹, 小野 啓, 穴井 元暢, 大西 由希子, 迫田 秀之, 荻原 健英, 木村 哲, 菊池 方利
    糖尿病 42(Suppl.1) S113-S113 1999年4月  
  • 大西 由希子, 船木 真理, 穴井 元暢, 荻原 健英, 迫田 秀之, 小野 啓, 藤城 緑, 浅野 知一郎
    糖尿病 42(Suppl.1) S245-S245 1999年4月  
  • 荻原 健英, 浅野 知一郎, 迫田 秀之, 大西 由希子, 小野 啓, 藤城 緑, 船木 真理, 佃 克則, 木村 哲, 菊池 方利
    糖尿病 42(Suppl.1) S257-S257 1999年4月  
  • 穴井 元暢, 浅野 知一郎, 片桐 秀樹, 犬飼 浩一, 大西 由希子, 迫田 秀之, 小野 啓, 木村 哲, 菊池 方利
    糖尿病 42(Suppl.1) S306-S306 1999年4月  
  • 浅野 知一郎, 佃 克則, 犬飼 浩一, 大西 由希子, 小野 啓, 藤城 緑, 矢崎 義雄
    日本内科学会雑誌 88(臨増) 255-255 1999年2月  
  • Motonobu Anai, Hiraku Ono, Makoto Funaki, Yasushi Fukushima, Kouichi Inukai, Takehide Ogihara, Hideyuki Sakoda, Yukiko Onishi, Yoshio Yazaki, Masatoshi Kikuchi, Yoshitomo Oka, Tomoichiro Asano
    Journal of Biological Chemistry 273(45) 29686-29692 1998年11月6日  
    Adipocytes contain three major substrate proteins of the insulin receptor, termed IRS-1, IRS-2, and IRS-3. We demonstrated that IRS-1 and IRS- 2 are located mainly in the low density microsome (LDM) fraction and are tyrosine phosphorylated in response to insulin stimulation, leading to phosphatidylinositol (PI) 3-kinase activation. In contrast, IRS-3 is located mainly in the plasma membrane (PM) fraction and contributes to PI 3-kinase activation in the PM fraction. The different cellular localizations of IRS proteins may account for the mechanism of insulin resistance induced by a high fat diet, considering that PI 3-kinase activation in the LDM fraction is reportedly essential for the translocation of GLUT4 in adipocytes. High fat feeding in rats increased both protein and mRNA levels of IRS-3 but decreased those of IRS-1 and IRS-2 in epididymal adipocytes. As a result, selective impairment of insulin-induced PI 3-kinase activation was observed in the LDM fraction, whereas PI 3-kinase activation was conserved in the PM fraction. This is the first report showing that different IRS proteins function in different subcellular compartments, which may contribute to determining the insulin sensitivity in adipocytes.

書籍等出版物

 1

講演・口頭発表等

 30

共同研究・競争的資金等の研究課題

 9